These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24470751)

  • 21. Do patient characteristics predict responsiveness to treatment of overactive bladder with antimuscarinic agents?
    Herschorn S; Kaplan SA; Sun F; Ntanios F
    Urology; 2014 May; 83(5):1023-9. PubMed ID: 24582119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of fesoterodine on quality of life: pooled data from two randomized trials.
    Kelleher CJ; Tubaro A; Wang JT; Kopp Z
    BJU Int; 2008 Jul; 102(1):56-61. PubMed ID: 18564231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial.
    Wagg A; Khullar V; Michel MC; Oelke M; Darekar A; Bitoun CE
    Neurourol Urodyn; 2014 Jan; 33(1):106-14. PubMed ID: 23460503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.
    Sánchez-Ballester F; Miranda P; Lizarraga I; Rejas J; Arumi D
    Actas Urol Esp; 2014 Apr; 38(3):156-63. PubMed ID: 24119382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of health care resources and associated costs in non-institutionalized vulnerable elders with overactive bladder treated with antimuscarinic agents in the usual medical practice.
    Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Aguado-Jodar A; Ruíz-Torrejón A
    Actas Urol Esp; 2014 Oct; 38(8):530-7. PubMed ID: 24630426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic management of overactive bladder.
    Lam S; Hilas O
    Clin Interv Aging; 2007; 2(3):337-45. PubMed ID: 18044184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fesoterodine.
    McKeage K; Keating GM
    Drugs; 2009; 69(6):731-8. PubMed ID: 19405552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder.
    Yamada S; Ito Y; Nishijima S; Kadekawa K; Sugaya K
    Pharmacol Ther; 2018 Sep; 189():130-148. PubMed ID: 29709423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights into factors associated with dose escalation.
    Cardozo L; Hall T; Ryan J; Ebel Bitoun C; Kausar I; Darekar A; Wagg A
    Int Urogynecol J; 2012 Nov; 23(11):1581-90. PubMed ID: 22576329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flexible dose fesoterodine in the treatment of overactive bladder (OAB).
    Tubaro A; De Nunzio C
    BJU Int; 2013 Aug; 112(3):281-2. PubMed ID: 23826839
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy and safety of fesoterodine treatment for overactive bladder symptoms in elderly women with and without hypertension.
    Yokoyama O; Yamagami H; Hiro S; Hotta S; Yoshida M
    Int J Urol; 2018 Mar; 25(3):251-257. PubMed ID: 29224251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial.
    Dubeau CE; Kraus SR; Griebling TL; Newman DK; Wyman JF; Johnson TM; Ouslander JG; Sun F; Gong J; Bavendam T
    J Urol; 2014 Feb; 191(2):395-404. PubMed ID: 23973522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.
    Nitti VW; Rovner ES; Bavendam T
    BJU Int; 2010 May; 105(9):1268-75. PubMed ID: 19889062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson's disease.
    Yonguc T; Sefik E; Inci I; Kusbeci OY; Celik S; Aydın ME; Polat S
    World J Urol; 2020 Aug; 38(8):2013-2019. PubMed ID: 31642953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.
    Leone Roberti Maggiore U; Salvatore S; Alessandri F; Remorgida V; Origoni M; Candiani M; Venturini PL; Ferrero S
    Expert Opin Drug Metab Toxicol; 2012 Nov; 8(11):1387-408. PubMed ID: 22871042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prominent complaint: a guide to medical therapy of overactive bladder syndrome in older women.
    Jafarabadi M; Ghanbari Z; Hashemi S; Nemati M; Haghollahi F; Azimi Nekoo E
    Acta Med Iran; 2015; 53(2):125-8. PubMed ID: 25725183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal women.
    Chughtai B; Forde JC; Buck J; Asfaw T; Lee R; Te AE; Kaplan SA
    Post Reprod Health; 2016 Mar; 22(1):34-40. PubMed ID: 26883688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Which anticholinergic drug for overactive bladder symptoms in adults.
    Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
    Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.